Categories

Above the Fold

TECHNOLOGY: Huge report on mobile solutions from BCC Consulting

There is a new and enormous report out, at a very attractive price, from BCC Consuting. It’s called Going Mobile: Choosing the Right Inpatient Solution. Be warned that this is a huge reference work of about 200 pages, not a quickie overview. (You should download the PDF–my link is to a overview screen). But the little I’ve dipped into so far seems to be very thorough research. Each company profiled has a 4 page review including details on their technology strategy, funding, customers, and applications.

If you are interested in this market this is a must have — and at this price, well let me say I hope that these guys don’t keep repeating this or they’ll put us all out of business.

PHARMA: Big pharma spends more on dividends than research? with UPDATE

This is brutal, but USA Today reports that equity analyst David Peterson from Bank of America Securities has a report out suggesting not that pharma spends more on marketing and gets more in profits than it spends on R&D, but that in recent years it’s spend more paying out dividends and on stock buy-backs than it’s spent on R&D. I’m not entirely sure these numbers are right. They seem to be comparing the entire health care sector’s R&D spend (at around 8%) with its use of dividends and buy-backs, whereas the sector’s R&D spend is heavily concentrated in big pharma (commonly 12-13% in R&D). But in any event it’s not great publicity for the industry, and Merck and Pfizer–the two biggest American companies–both had much more spending on dividends and buy-backs than on research:

Pfizer, the world’s largest drugmaker, spent $22.2 billion on stock buybacks and dividends, or 210% of what was spent on research. Merck returned $7.3 billion, or 143% of research spending. Merck spokeswoman Anita Larsen would not comment on the Bank of America report, but she said the company’s R&D budget grew 19% in 2003 to nearly $3.2 billion. Pfizer did not respond to a request for comment.

Some years back when I did a lot of business with a large pharma, the strategists there use to joke about the “bank in New York” that owned them, and how it restricted what they could do. My sense was that the people there wanted to do the right thing, in terms of spending money on improving their products and improving health care delivery. But it seems that they weren’t joking too much about the influence of the “banking” side of their business. And the resulting PR fallout continues to make pharma’s life harder.

UPDATE: Dave Schuler from The Glittering Eye tells me that:

I reported this six months ago It’s obvious to anyone who can read an annual report. But even more interesting is the behavior over time. Year-to-year increases in R&D spending vary with the rate of inflation NOT with profits. The conclusion that leaps to mind on this behavior is that Big Pharma sees their core business something other than developing new drugs.

Given that pharma spends two and half times on sales, marketing and GA what they do on R&D, and that the model successful company over the last decade has been Pfizer which did it by hiring the biggest and best sales force, I agree.

POLICY: Of unbiased Republicans, Thorpe, Kerry and uninsured kids, with UPDATE

Ken Thorpe writes in the NEJM on the uninsured. He’s been in the Clinton Administration, and he’s the author of the study that says the Kerry plan’s cost will be in the $650 billion range rather than the AEI’s $1.5 trillion estimate. So you can take his view the way you want to. But what he basically says is that both Bush and Kerry’s plans are incremental and neither of them will cure the problem of the uninsured. Then again I just had dinner with an (only) Fox-News watching, Bush supporter from Texas who told me –in all seriousness–that not only was my analysis of the health care system biased because the richest people in the world come here for their medical care (the Sultan of Brunei?) and so we have the best system in the world–whatever the Economist (which prefers the Swiss system) and WHO say (they rank the French first). He also told me that Iraq is in good shape, the Abu Grahib scandal wasn’t a big deal, all the networks are biased in Kerry’s favor and that uninsurance for 45 million wasn’t a problem. So given that’s the attitude of many on the Republican side (and I’m sure it is), it’s unlikely that this post is going to change many minds. However, Thorpe correctly says that:

Adults and children without insurance are given diagnoses at later stages of illness, receive fewer preventive and curative medical services, and have worse health care outcomes than those with insurance…..First, Kerry would extend coverage by Medicaid and the State Children’s Health Insurance Program (SCHIP) to people who are currently ineligible for such coverage — single adults and childless couples living below the poverty line and parents with incomes of less than 200 percent of the poverty line. He has also proposed extending the same coverage to more children by raising the cutoff level to 300 percent of the poverty line. Instead of continuing today’s federal–state matching arrangements in these programs, Kerry would have the federal government finance 100 percent of the costs of the expansion. Full federal funding is likely to result in higher rates of program enrollment.

This past week a progressive pressure group, Vote Kids, introduced several leading pediatricians in a Washington DC press conference to make a joint statement about children’s health care in America. The pediatricians included six past presidents of the American Academy of Pediatrics all supporting Kerry’s effort to extend coverage to all children. HHS Secretary Thompson responded to this week’s activity by calling the pediatricians “demagogues and said: “It is absurd and despicable that doctors are playing politics with children’s lives“. That sounds a little over the top to me, even though Sydney at Medpundit points out that some doctors (including her) don’t agree with the AAP on this. (Syd also has this great post on the relative risk of Vioxx, which I agree with BTW, showing my libertarian side…). Mitch Arnowitz from Vote Kids wrote to me saying:

8 million children and youth don’t have health insurance. We think that the present administration does not have a plan to provide health coverage to America’s children, and that their current tax and budget priorities are eroding hard won health care gains for children.

That statement is undeniably true so I’m going to respond to my Texan friend’s charge of bias by being biased in favor of the truth. I try not to use this blog as a soapbox, but try reading this story about a young woman born with a “pre-existing condition” who is disabled and has a terrible story, and you’ll understand why emotionally I feel that we need a single universal insurance pool for the most vulnerable. Kids are the cheapest and easiest to cover, and there is no way that even the crustiest Texan Republican can explain to me that its their fault if they are uninsured. So morally I think we should get them coverage.

You can give to Vote Kids, here. And in equal fairness you can give to Bush here. How unbiased is that?!!

UPDATE: Linkmeister Steve accuses me of going into “he said, she said” here without actually calling Thompson or Vote Kids on the truth. He cites a neat article from the Columbia Journalism Review, which tries to tell the truth on the candidate’s health care plan objectively rather than just allow each side’s spin to come out unhindered. The way it should be done is “he said, she said, we say”.

I honestly think I do the “we say” bit but let me reiterate. Vote Kids is right, in that there are more than 8 million uninsured kids and that uninsured kids (and adults) tend to be poorer and get fewer health services than insured ones. The KFF factsheet shows that. Tommy Thompson claims that Bush has done great stuff for kids–and to be fair the number of uninsured kids has gone down, due to SCHIP and Medicaid. But that’s not good enough, and the Bush “program” has no plans to further reduce that number. The Kerry plan, not that it’ll pass as is, does. And furthermore, insuring kids is relatively cheap and very good value in terms of future benefit to society–second only to getting them an education. We wouldn’t (I hope) as a society accept non-universal education for kids. At least Kerry wants to get us there for healthcare.

PHARMA: The Industry Veteran takes THCB to task for its wishy-washy moderation

I thought that my HSA post from Friday might stir one of my noted contributors into action. Not so; instead The Industry Veteran thinks that in a recent post where I’ve been a little critical of Marcia Angell, I’ve misinterpreted her and, worse, been overly cosy-ing up to big Pharma. He writes to me:

The fact that you printed a reasonable exchange of views on single-payer vs. HSAs is not what leads me to second the suggestion that you sit down and apply old compresses. It’s the fact that twice earlier this week you showed signs of developing Bush-Cheney patellar reflexes. First you throw your two cents into the Vioxx scandal by admonishing people not to be too hard on Big Pharma. I suppose that, in essence, THCB is a promotional site for your professional services, but I was still astonished by such a bald-faced plug. Then you proceeded to review Marcia Angell’s radio talk by claiming that the logic of her argument must inevitably lead to a misguided nationalization of the pharmaceutical industry. I half expected that you would then start calling her a flip-flopper and push your surrogates to claim she never really edited the New England Journal of Medicine.

Now after all, it is your Blog so I won’t dispute your right to use it for cozying up. It’s just that I had always considered you a man of advanced Fabian persuasions, one who reminded me of my former LSE prof, Richard Titmuss. It was disappointing, for that reason, to see you adopting the postures normally taken by those who favor a “competitive, materialistic, acquisitive society based on hierarchies of power and privilege.” as for Dr. Angell, I know that she explicitly disavows the idea of a nationalized pharmaceutical industry. Her position parallels that of Merrill Goozner, Sid Wolfe and an ample number of other industry critics who merely seek greater transparency (disclosing actual R&D costs, publishing the results of all trials, et.al.), the strict removal of marketing concerns from continuing medical education, greater supervision and penalties concerning conflicts of interest, and an allocation of R&D resources based more on medical needs and less on the profits from exploiting fetishism. This last goal, for example, can be readily accomplished by maintaining patent and tax benefits for company efforts to develop products that genuinely advance the standards of medical care and by denying these advantages for products that create four-hour erections, smooth wrinkles by paralyzing facial nerves or act as high-tech versions of Spanish fly. In fact I don’t know any experienced industry people who would favor a nationalized system. In a government-managed system we might still be waiting for penicillin while your AWOL-playboy President would forbid potentially fruitful areas of research in an effort to appease his base constituency of self-righteous, religious morons.

I am of course expecting Fred Hassan and Hank McKinnell to drop the bribe money off any day now….

POLICY: No on Prop. 72 ad busted for faking it

Proposition 72 is a referendum on the California pay or play bill that passed in the waning days of Gray Davis ill fate-second term before the Governator swept all before him a year ago. The Yes on 72 bill has been out with some TV commercials–most of their money comes from Unions while the players like Wellpoint are neutral. The opponents are the large fast food chains who would be forced to provide health care coverage to their workers. I listed out who was pro- and con a while back, with the those opposing having raised much more money, of course.

The bill won’t do too much about California’s uninsurance crisis–maybe putting 1.4 million out of 6 million uninsured into coverage. The problem is concentrated in smaller firms, who politically can’t be forced in providing coverage. But a band-aid on a wound is better than nothing for supporters of universal insurance. My feeling is that big businesses that do not offer benefits (e.g. the Walmarts of the world)are competing unfairly with those who do–while the taxpayer picks up the tab. A RAND study shows that 95% of businesses with more than 50 workers already offer insurance to their employees. (I mean offer insurance that is taken up, as offering insurance that the worker can’t afford is a cop out). But 15% of all workers in that size of firm do not get coverage, mostly because they can’t afford (see chart 9). The bill maxes out the workers premium share at 20%.

So it’s the big businesses paying low wages (i.e. fast food) that are being targeted here. And most of them can’t easily move, unless Los Angelinos are prepared to drive to Phoenix for their burgers. Of course the No on Prop 72 folks are keen to suggest that this bill will put mom & pop businesses under, but the bill doesn’t apply to businesses with fewer than 50 employees. So it’s a little amusing that the “No on 72” guys got caught faking their most seen ad. It was supposed to be a poor immigrant restaurant owner. But the restaurant in question wouldn’t be affected by the bill, and the “owner” was an actress. Oops.

For more on this and other California propositions see the California HealthCare Foundation site.

POLICY: HSAs Redux, and “A short response on a short bit of logic”

A couple of days back in a piece on HSAs I challenged someone, anyone to speak up for HSAs against this criticism from Don McCanne. While I’m not a straight single payer advocate like Don, we both believe in one risk pool/universal insurance. And HSAs destroy that concept. Here’s Don’s logic in full:

Imagine everyone having a health savings account (HSA) and a low cost, high deductible insurance plan. Now let’s fund our entire health care system, currently at $1.8 trillion, with the HSAs and high deductible plans. Keep in mind that 80% of health care costs are used by the 20% of individuals with serious acute and chronic disorders.

Current contributions for HSAs are capped at $2600 for individuals and $5150 for families. For illustrative purposes only, let’s assume that each individual has $2000 in an HSA. That means that the 294 million U.S. citizens would have $588 billion in HSAs. For the 20% with significant needs, their $117 billion would be rapidly depleted, having been spent of health care. The healthy 80% might use an average of $300 per person in incidental health care costs, depleting their accounts of $70 billion. The “beauty” of HSAs is that the $401 billion remaining in the HSAs of the 80% who are healthy will be converted into retirement pensions. That’s a great deal for the majority of individuals who remain healthy. But that removes about $400 billion from the $1.8 trillion that we are already spending.

HSAs will have funded $187 billion of the $1.8 trillion, leaving costs of $1.61 trillion for the catastrophic care of the 20% of individuals with greater needs. But after the HSA funds are removed from the equation, there is only $1.21 trillion left to pay for care that currently costs $1.61 trillion.

Where will the $400 billion shortfall come from? Not from most of those with greater needs since current health plans already fail to provide adequate financial security, and this would add an average additional burden of $6800 per person. The only practical solution would be to increase the premiums for the high deductible coverage to a level that would fund the full balance of the $1.8 trillion that we are spending.

There are two significant consequences of this. First, the low cost, high deductible plans would no longer be low cost. Second, there is a perversity of the fundamental principle of health insurance, in which funds of the healthy normally help to pay for care for the sick, in that, with HSAs, the funds of the sick help to pay for the retirement accounts of the healthy.

Landon Alger (the government employee you may recall from his contributions a few weeks back) took up the challenge, and just to really annoy The Industry Veteran, I’m printing it here. Interestingly enough there is a teensy bit of common ground between him and McCanne, the single payer advocate. I’m coming over all moderate and centrist. Perhaps I’d better go sit down. Here’s Langdon’s piece:

Single payer lunatic Don McCanne provides a simple example of what can happen when HSAs are applied on a macro-scale. The healthy 80% realize savings not just on health insurance premiums, but also on actual healthcare costs. They are definite winners (therefore implying a loser) that get a nifty new savings vehicle-a health pension. These individuals have no need for the single payer paradigm and would not benefit from such a system. For these 80%, the single payer system introduces inefficiencies and would add to our national healthcare expenditures.

The remaining 20% that need 80% of the healthcare dollars (these ratios are not set in stone and one of the goals of national healthcare policy should be to flatten the curve) are now definitely losing out at this point. They need the taxpayer subsidized single payer type system and aggressive, outcome-incentive based disease management programs on a national level. While it is surely difficult to implement a system where individuals must qualify into the “single payer system” (yes, I know, it’s really not pure single payer anymore), there is no definite exclusiveness of HSAs and single payer. McCanne isn’t wrong, just incomplete.

Additionally, current HSA law does have a few flawed provisions. The HSA should only be able to be used for healthcare costs, and not simply another IRA once a person gets to age 65. And at death any remaining HSA balance should be forfeited into the single payer system.

QUALITY: Wennberg’s Dartmouth team shows enormous variation even in the “best hospitals”

More just astonishing research from Wennberg and his team. The latest study shows that whatever the US News and World Report’s ranking of a hospital, some top centers do lots more to a patient close to the end of life than others. In other words the immense practice variation that Wennberg unveiled in the early 1970s continues, even within the elite hospitals in the nation.

And the differences within this elite group are very large. To get a quick summary look at the this AP story. For example, at Mt Sinai in New York LOS was twice that of the Mayo Clinic, while at Cedars-Sinai in Los Angeles, sick patients stayed in the ICU three times as long as at the Mass General in Boston. There’s much more in the full article in Health Affairs. Something is clearly wrong when the best medicine in America is so different from the best medicine in America.

Another article from part of the same Dartmouth group (led by Elliott Fisher, and including Jack’s son David Wennberg) looks at the impact of ICU services in those same elite hospitals on patient outcomes, and it comes up with this pretty stunning conclusion:

Major U.S. AMCs differ dramatically in the overall intensity of services they provide to similar patients. The increased intensity does not appear to be associated with higher quality of care or to result in better survival. Patients in the higher-intensity hospitals simply spend more time in the hospital and intensive care unit (ICU); have more frequent physician visits (especially in the inpatient setting); have more specialists involved in their care; and receive more imaging services, diagnostic testing, and minor (but not major) procedures. The similar results achieved with markedly different levels of resource inputs imply large differences in the longitudinal efficiency of chronic disease care across these hospitals.

Given that they are handing out Nobel prizes at this time of year, is there a more important body of work in economics that has yet to be recognized? In case you wondered, here’s a list of Nobel prize winners in Economics and even though his formal training wasn’t in economics, I think Wennberg would fit right in with this group.

PHARMA: Marcia Angell rips big Pharma a new one

So Marcia Angell’s talk at the commonwealth Club was all that I expected. She is witty and charming and she really laid into big Pharma. Big pharma to her has no redeeming qualities. Everything they do is wrong and all they do is run biased clinical trials, and pay off the doctors (majority) and the politicians (minorly). A review of her book in the NEJM(BTW you can go to BugmeNot to break into these password protected sites, shh!!) from a Canadian Medical Association doc echoes her points, even though rational people (i.e. me) think that she was a little over the top.

I hope that there is a middle ground. Drugs save huge amounts of other health care costs and they do keep people alive who would otherwise be dead. If you read on in the review you get to this passage.

Angell’s concluding chapter, the least convincing one in an otherwise fascinating and penetrating book, contains the solutions, all of them predictable (and probably unattainable): control me-too drugs, re-empower the FDA, oversee Big Pharma’s clinical research, curb patent length and abuse, keep Big Pharma out of medical education, make company financial statements transparent (so we can tell what the costs of research really are, as distinct from marketing), and impose price controls or guidelines. Granted, the problems are so prevalent and the corporate tentacles so entwined with our way of being that it is hard to see what else to recommend.

But perhaps Angell is right. We must change the way we manage research and the development and distribution of new drugs. Not only are health and health care at risk, but so are the research enterprise and the reputations of universities and governments. The integrity of scientific research is too important to be left to the invisible hand of the marketplace.

The problem is that this logically leads to the idea that the only solution is heavy government regulation or even the total nationalization of the pharma business. Realistically, that’s not going to happen. So if you go to that extreme, all you can expect from pharma is a circling of the wagons and an attempt to keep paying off their servants in Congress and the Administration.

There needs to be a middle way, and I gave some ideas earlier this week about what that looks like. I don’t think Angell’s approach will get us there, even if 90% of what she says is true.

TECHNOLOGY: Very short memories in the PHR space

REDMedic is a start-up building a personal health record prodcut aimed directly at end-user consumers. Their wrinkle in the space is that people can take a key-fob or card with them so that if they get into an accident an emergency room nurse can look up their information online via an emergency log-in screen. (Full disclosure: I discussed a possible consulting role with REDMedic a year or so ago but never did anything with them). Nothing wrong with this idea. I thought it was pretty good when i-Beacon (my company) did it in 2000. Dr Koop thought they had it down when they did it in 1998, and Medicalogic had the same conclusion in 1999 with their PHR. Of course the same was true for PersonalMD, HealthAtoZ, iMetrikus and about 35 other companies, including WellMed which survived and is now part of WebMD. Note that they survived and everyone else didn’t. Which may give you a hint about what I told REDMedic were the dangers in their business model.

I have no problem with REDMedic claiming this is a revolutionary idea (although it isn’t as PersonalMD had exactly the same ER room access to the web/fax “emergency card” in 1999)–after all every start up should blow its own horn. What slightly annoys me is that they’ve convinced a not very worldly journalist at Information Week of the same thing in an article called Digital Health Records Move Closer To Reality. Come on team, 2000 wasn’t that long ago. Surely someone apart from me remembers it?

I genuinely hope that REDMedic’s service aimed at consumers takes off, though at $36 a year and no one using PHRs, they are at the very bottom end of the “S” curve adoption, and likely to stay there for some time. Recasting their service as a web-based Medicalert bracelet may even work, as people are more web savvy than they were a few years back. But the same issues that stopped the other 35 companies from having success–such as the unwillingness of providers to get data from their systems into the PHR, and health plans deciding that they didn’t have to improve their web service to their consumers in order to keep them as members–have not gone away to any appreciable extent. However, the online PHR, like online banking, is one of those things that will take off at some point, and whoever is alive and kicking in the space then may make out well.

Meanwhile, if you want to get into this business easily, there’s some very nifty software sitting in a box in San Francisco that I could get into your hands cheap!

assetto corsa mods